From clinical trials to clinical use of checkpoint inhibitors for patients with metastatic urothelial cancer

Rosa Tambaro; Marilena Di Napoli; Carmela Pisano; Sabrina Chiara Cecere; Laura Attademo; Sabrina Rossetti; Florinda Feroce; Sergio Setola; Daniela Califano; Daniela Russo; Anna Spina; Sisto Perdonà; Alessandro Izzo; Sandro Pignata

doi:10.2217/imt-2020-0128

From clinical trials to clinical use of checkpoint inhibitors for patients with metastatic urothelial cancer

Rosa Tambaro, Marilena Di Napoli, Carmela Pisano, Sabrina Chiara Cecere, Laura Attademo, Sabrina Rossetti, Florinda Feroce, Sergio Setola, Daniela Califano, Daniela Russo, Anna Spina, Sisto Perdonà, Alessandro Izzo, Sandro Pignata

Istituto Nazionale Tumori Fondazione G. Pascale

Research output: Contribution to journal › Review article › peer-review

Abstract

Monoclonal antibodies targeting the checkpoint inhibitors (CPIs), programmed cell death protein-1 or programmed cell death ligand-1, are changing the landscape of urothelial carcinoma therapeutics. Overall, clinical studies in metastatic or advanced urothelial cancer showed that CPIs provided a slight improvement in survival and a relevant advantage in safety, compared with chemotherapy. After reviewing published and ongoing trials, the authors discuss expected answers to unmet needs, with a special attention to the research of biological markers for patients with urothelial cancer eligible for treatment with CPIs in this article.

Original language	English
Pages (from-to)	67-77
Number of pages	11
Journal	Immunotherapy
Volume	13
Issue number	1
DOIs	https://doi.org/10.2217/imt-2020-0128
Publication status	Published - Jan 2021

Keywords

atezolizumab
checkpoint inhibitors
durvalumab
immunotherapy
nivolumab
PD-1
PD-L1
urothelial cancer

ASJC Scopus subject areas

Immunology and Allergy
Immunology
Oncology

Access to Document

10.2217/imt-2020-0128

Fingerprint Dive into the research topics of 'From clinical trials to clinical use of checkpoint inhibitors for patients with metastatic urothelial cancer'. Together they form a unique fingerprint.

Cite this

From clinical trials to clinical use of checkpoint inhibitors for patients with metastatic urothelial cancer. / Tambaro, Rosa; Napoli, Marilena Di; Pisano, Carmela ; Cecere, Sabrina Chiara ; Attademo, Laura; Rossetti, Sabrina; Feroce, Florinda ; Setola, Sergio ; Califano, Daniela ; Russo, Daniela; Spina, Anna; Perdonà, Sisto ; Izzo, Alessandro ; Pignata, Sandro.

In: Immunotherapy, Vol. 13, No. 1, 01.2021, p. 67-77.

Research output: Contribution to journal › Review article › peer-review

Tambaro, Rosa ; Napoli, Marilena Di ; Pisano, Carmela ; Cecere, Sabrina Chiara ; Attademo, Laura ; Rossetti, Sabrina ; Feroce, Florinda ; Setola, Sergio ; Califano, Daniela ; Russo, Daniela ; Spina, Anna ; Perdonà, Sisto ; Izzo, Alessandro ; Pignata, Sandro. / From clinical trials to clinical use of checkpoint inhibitors for patients with metastatic urothelial cancer. In: Immunotherapy. 2021 ; Vol. 13, No. 1. pp. 67-77.

@article{ef06b1842a334062968d9ee600aed8d7,

title = "From clinical trials to clinical use of checkpoint inhibitors for patients with metastatic urothelial cancer",

abstract = "Monoclonal antibodies targeting the checkpoint inhibitors (CPIs), programmed cell death protein-1 or programmed cell death ligand-1, are changing the landscape of urothelial carcinoma therapeutics. Overall, clinical studies in metastatic or advanced urothelial cancer showed that CPIs provided a slight improvement in survival and a relevant advantage in safety, compared with chemotherapy. After reviewing published and ongoing trials, the authors discuss expected answers to unmet needs, with a special attention to the research of biological markers for patients with urothelial cancer eligible for treatment with CPIs in this article. ",

keywords = "atezolizumab, checkpoint inhibitors, durvalumab, immunotherapy, nivolumab, PD-1, PD-L1, urothelial cancer",

author = "Rosa Tambaro and Napoli, {Marilena Di} and Carmela Pisano and Cecere, {Sabrina Chiara} and Laura Attademo and Sabrina Rossetti and Florinda Feroce and Sergio Setola and Daniela Califano and Daniela Russo and Anna Spina and Sisto Perdon{\`a} and Alessandro Izzo and Sandro Pignata",

note = "Funding Information: Editorial assistance was performed by L Brogelli, B Bartolini and A Shah of Polistudium srl (Milan, Italy); this assistance was supported by internal funds. Publisher Copyright: {\textcopyright} 2021 Copyright: Copyright 2020 Elsevier B.V., All rights reserved.",

year = "2021",

month = jan,

doi = "10.2217/imt-2020-0128",

language = "English",

volume = "13",

pages = "67--77",

journal = "Immunotherapy",

issn = "1750-743X",

publisher = "Future Medicine Ltd.",

number = "1",

}

TY - JOUR

T1 - From clinical trials to clinical use of checkpoint inhibitors for patients with metastatic urothelial cancer

AU - Tambaro, Rosa

AU - Napoli, Marilena Di

AU - Pisano, Carmela

AU - Cecere, Sabrina Chiara

AU - Attademo, Laura

AU - Rossetti, Sabrina

AU - Feroce, Florinda

AU - Setola, Sergio

AU - Califano, Daniela

AU - Russo, Daniela

AU - Spina, Anna

AU - Perdonà, Sisto

AU - Izzo, Alessandro

AU - Pignata, Sandro

N1 - Funding Information: Editorial assistance was performed by L Brogelli, B Bartolini and A Shah of Polistudium srl (Milan, Italy); this assistance was supported by internal funds. Publisher Copyright: © 2021 Copyright: Copyright 2020 Elsevier B.V., All rights reserved.

PY - 2021/1

Y1 - 2021/1

N2 - Monoclonal antibodies targeting the checkpoint inhibitors (CPIs), programmed cell death protein-1 or programmed cell death ligand-1, are changing the landscape of urothelial carcinoma therapeutics. Overall, clinical studies in metastatic or advanced urothelial cancer showed that CPIs provided a slight improvement in survival and a relevant advantage in safety, compared with chemotherapy. After reviewing published and ongoing trials, the authors discuss expected answers to unmet needs, with a special attention to the research of biological markers for patients with urothelial cancer eligible for treatment with CPIs in this article.

AB - Monoclonal antibodies targeting the checkpoint inhibitors (CPIs), programmed cell death protein-1 or programmed cell death ligand-1, are changing the landscape of urothelial carcinoma therapeutics. Overall, clinical studies in metastatic or advanced urothelial cancer showed that CPIs provided a slight improvement in survival and a relevant advantage in safety, compared with chemotherapy. After reviewing published and ongoing trials, the authors discuss expected answers to unmet needs, with a special attention to the research of biological markers for patients with urothelial cancer eligible for treatment with CPIs in this article.

KW - atezolizumab

KW - checkpoint inhibitors

KW - durvalumab

KW - immunotherapy

KW - nivolumab

KW - PD-1

KW - PD-L1

KW - urothelial cancer

UR - http://www.scopus.com/inward/record.url?scp=85097581687&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85097581687&partnerID=8YFLogxK

U2 - 10.2217/imt-2020-0128

DO - 10.2217/imt-2020-0128

M3 - Review article

C2 - 33045887

AN - SCOPUS:85097581687

VL - 13

SP - 67

EP - 77

JO - Immunotherapy

JF - Immunotherapy

SN - 1750-743X

IS - 1

ER -